Renaparin Market Summary

Key Factors Driving Renaparin Growth

1. High unmet need associated with ischemia-reperfusion injury (IRI): Renaparin is being developed by Corline Biomedical to prevent ischemia-reperfusion injury in transplanted kidneys. During preservation, the donor kidney is deprived of blood flow and subsequently exposed to reperfusion when transplanted. Corline states that IRI can contribute to delayed graft function (DGF) in up to 40% of kidney transplants, making prevention of graft injury an important clinical need.

2. Large and recurring kidney-transplant population: Corline estimates that more than 70,000 kidney transplants are performed annually worldwide, including approximately 33,000 in the EU and U.S. This provides a recurring potential treatment population if Renaparin ultimately demonstrates efficacy and obtains approval. The broader shortage of donor organs also creates an incentive for technologies that can improve the usability and performance of transplanted kidneys.

3. Differentiated ex-vivo administration: Unlike systemic therapies aimed at treating consequences of graft injury after transplantation, Renaparin is administered directly to the donor kidney ex vivo before transplantation by flushing the kidney's vascular system. The approach is intended to repair/protect the damaged vascular endothelium and reduce local inflammatory and thrombotic responses while limiting systemic exposure. This differentiated administration could facilitate integration into the existing organ-preservation/transplant workflow.

4. Encouraging long-term clinical follow-up: In July 2026, Corline reported 60-month follow-up from the STARS-nob study. All Renaparin-treated kidneys retained function at five years. Among five matched donor-kidney pairs, Renaparin-treated kidneys had better eGFR in 2/5 pairs, similar eGFR in 2/5, and lower eGFR in 1/5. At 36 months, mean eGFR was approximately 48 vs. 40 mL/min/1.73 m², representing about a 20% numerical difference. Corline emphasized that the sample was small and not statistically powered to establish efficacy, but the results support further development.

5. Progression toward a larger controlled Phase II study: RENAPAIR 02 is designed as a randomized, single-blind, no-treatment-controlled Phase II study in deceased-donor kidney transplantation. The approved study is designed for approximately 80 patients across Germany, Austria and the UK, with kidney function measured by eGFR at three months as the primary endpoint. Renaparin-treated kidneys receive the therapy at least 90 minutes before transplantation, allowing the intervention to fit into the transplantation process.

Renaparin Recent Developments

Renaparin is currently in a holding phase while its developer, Corline Biomedical AB, actively seeks a licensing partner or financing to advance its clinical development.

“Renaparin Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Renaparin for potential indication like Renal transplant rejection in the 7MM. A detailed picture of Renaparin’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Renaparin for potential indications. The Renaparin market report provides insights about Renaparin’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Renaparin performance, future market assessments inclusive of the Renaparin market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Renaparin sales forecasts, along with factors driving its market.

Renaparin Drug Summary

Renaparin is an investigational organ-preservation therapy developed by Corline Biomedical AB for use in kidney transplantation, particularly to reduce ischemia-reperfusion injury (IRI) and delayed graft function (DGF) following transplantation of kidneys from deceased donors. Renaparin is based on a Corline heparin conjugate (CHC; PD00459) that is designed to bind locally to the vascular endothelium of the donor kidney and provide a localized heparin-like protective effect without requiring systemic administration. Unlike conventional drugs administered to the transplant recipient, Renaparin is applied ex vivo to the donor kidney by adding it to the organ-preservation solution during cold storage or hypothermic machine perfusion before transplantation. By coating damaged areas of the renal vascular endothelium, the therapy is intended to reduce local coagulation and inflammatory/innate immune responses triggered when blood flow is restored, thereby protecting the graft from IRI and supporting early kidney function. Renaparin has received EU orphan-drug designation and has progressed into clinical development; the Phase I RENAPAIR 01 study evaluated ex-vivo treatment of deceased-donor kidneys before transplantation, while the Phase II RENAPAIR 02 study was designed to assess its efficacy and safety in recipients of kidneys at high risk of IRI and DGF. The Phase II program is intended to evaluate outcomes including early graft function, dialysis requirements, primary non-function, and safety. Renaparin remains an investigational, non-authorized product and is not currently approved for routine clinical use. The report provides Renaparin’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Renaparin Market Report

The report provides insights into:

• A comprehensive product overview including the Renaparin MoA, description, dosage and administration, research and development activities in potential indication like Renal transplant rejection.
• Elaborated details on Renaparin regulatory milestones and other development activities have been provided in Renaparin market report.
• The report also highlights Renaparin‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Renaparin market report also covers the patents information, generic entry and impact on cost cut.
• The Renaparin market report contains current and forecasted Renaparin sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Renaparin market report also features the SWOT analysis with analyst views for Renaparin in potential indications.

Methodology

The Renaparin market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Renaparin Analytical Perspective by DelveInsight

• In-depth Renaparin Market Assessment

This Renaparin sales market forecast report provides a detailed market assessment of Renaparin for potential indication like Renal transplant rejection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Renaparin sales data uptil 2034.

• Renaparin Clinical Assessment

The Renaparin market report provides the clinical trials information of Renaparin for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Renaparin Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Renaparin Market Potential & Revenue Forecast

• Projected market size for the Renaparin and its key indications
• Estimated Renaparin sales potential (Renaparin peak sales forecasts)
• Renaparin Pricing strategies and reimbursement landscape

Renaparin Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Renaparin Market positioning compared to existing treatments
• Renaparin Strengths & weaknesses relative to competitors

Renaparin Regulatory & Commercial Milestones

• Renaparin Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Renaparin Clinical Differentiation

• Renaparin Efficacy & safety advantages over existing drugs
• Renaparin Unique selling points

Renaparin Market Report Highlights

• In the coming years, the Renaparin market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Renaparin companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Renaparin’s dominance.
• Other emerging products for Renal transplant rejection are expected to give tough market competition to Renaparin and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Renaparin in potential indications.
• Analyse Renaparin cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Renaparin sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Renaparin in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Renaparin? How strong is Renaparin’s clinical and commercial performance?
• What is Renaparin’s clinical trial status in each individual indications such as Renal transplant rejection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Renaparin Manufacturers?
• What are the key designations that have been granted to Renaparin for potential indications? How are they going to impact Renaparin’s penetration in various geographies?
• What is the current and forecasted Renaparin market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Renaparin in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Renaparin for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Renaparin? What is the duration of therapy and what are the geographical variations in cost per patient?